Global Markets Direct’s, ‘Saniona AB – Product Pipeline Review -2015′, provides an overview of the Saniona AB’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Saniona AB’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides brief overview of Saniona AB including business description, key information and facts, and its locations and subsidiaries
• The report reviews current pipeline of Saniona AB’s human therapeutic division and enlists all their major and minor projects
• The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
• Special feature on out-licensed and partnered product portfolio
• The report summarizes all the dormant and discontinued pipeline projects
• Latest company statement
• Latest news and deals relating to the Saniona AB’s pipeline products

Reasons to buy

• Evaluate Saniona AB’s strategic position with total access to detailed information on its product pipeline
• Assess the growth potential of Saniona AB in its therapy areas of focus
• Identify new drug targets and therapeutic classes in the Saniona AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
• Develop strategic initiatives by understanding the focus areas of Saniona AB and exploit collaboration and partnership opportunities
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by identifying the most promising pipeline of Saniona AB
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Explore the dormant and discontinued projects of Saniona AB and identify potential opportunities in those areas
• Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Saniona AB Snapshot 6
Saniona AB Overview 6
Key Information 6
Key Facts 6
Saniona AB - Research and Development Overview 7
Key Therapeutic Areas 7
Saniona AB - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Saniona AB - Pipeline Products Glance 17
Saniona AB - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Saniona AB - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Saniona AB - Drug Profiles 21
tesofensine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Product Description 23
Mechanism of Action 23
R&D Progress 23
AN-788 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
metoprolol + tesofensine 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
N-S2359 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
AN-346 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AN-363 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
AN-470 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
AN-761 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
NS-9283 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule to Activate Kv7.2 and Kv7.3 Channels for Epilepsy and Pain 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule to Activate TREK for Pain 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecule to Agonize GABA Alpha 4 Delta Receptor for Sleep Disorders, Stress and Autism 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecule to Agonize GABAA Receptor Subunit Alpha-4 and Gamma for Epilepsy 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule to Agonize nAChR Alpha6 for Parkinson's Disease 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule to Agonize nAChR Alpha7 for Pain 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecule to Block TREK for Depression 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecule to Inhibit Monoamine Reuptake for Pain 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Saniona AB - Pipeline Analysis 45
Saniona AB - Pipeline Products by Target 45
Saniona AB - Pipeline Products by Route of Administration 46
Saniona AB - Pipeline Products by Molecule Type 47
Saniona AB - Pipeline Products by Mechanism of Action 48
Saniona AB - Recent Pipeline Updates 50
Saniona AB - Dormant Projects 51
Saniona AB - Discontinued Pipeline Products 52
Discontinued Pipeline Product Profiles 52
N-S2359 52
tesofensine 52
Saniona AB - Locations And Subsidiaries 53
Head Office 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables

Saniona AB, Key Information 6
Saniona AB, Key Facts 6
Saniona AB - Pipeline by Indication, 2015 9
Saniona AB - Pipeline by Stage of Development, 2015 10
Saniona AB - Monotherapy Products in Pipeline, 2015 11
Saniona AB - Combination Treatment Modalities in Pipeline, 2015 12
Saniona AB - Partnered Products in Pipeline, 2015 13
Saniona AB - Partnered Products/ Combination Treatment Modalities, 2015 14
Saniona AB - Out-Licensed Products in Pipeline, 2015 15
Saniona AB - Out-Licensed Products/ Combination Treatment Modalities, 2015 16
Saniona AB - Phase II, 2015 17
Saniona AB - Phase I, 2015 18
Saniona AB - Preclinical, 2015 19
Saniona AB - Discovery, 2015 20
Saniona AB - Pipeline by Target, 2015 45
Saniona AB - Pipeline by Route of Administration, 2015 46
Saniona AB - Pipeline by Molecule Type, 2015 47
Saniona AB - Pipeline Products by Mechanism of Action, 2015 49
Saniona AB - Recent Pipeline Updates, 2015 50
Saniona AB - Dormant Developmental Projects,2015 51
Saniona AB - Discontinued Pipeline Products, 2015 52

List of Figures

Saniona AB - Pipeline by Top 10 Indication, 2015 8
Saniona AB - Pipeline by Stage of Development, 2015 10
Saniona AB - Monotherapy Products in Pipeline, 2015 11
Saniona AB - Pipeline by Top 10 Target, 2015 45
Saniona AB - Pipeline by Top 10 Route of Administration, 2015 46
Saniona AB - Pipeline by Top 10 Molecule Type, 2015 47
Saniona AB - Pipeline Products by Top 10 Mechanism of Action, 2015 48